OneSource Specialty Pharma Ltd
Incorporated in 2007, OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of bio
logical drug products in various injectable formats. It also offers end-to-end CDMO
services across all phases of pre-clinical
and clinical development and commercial
supply of biologics[1]
- Market Cap ₹ 18,794 Cr.
- Current Price ₹ 1,639
- High / Low ₹ 2,026 / 1,057
- Stock P/E
- Book Value ₹ 509
- Dividend Yield 0.00 %
- ROCE 0.57 %
- ROE -1.09 %
- Face Value ₹ 1.00
Pros
Cons
- Stock is trading at 3.23 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -2.39% over last 3 years.
- Promoters have pledged 38.4% of their holding.
- Company has high debtors of 177 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 21 | 132 | 39 | 172 | 1,445 | 1,422 | |
| 93 | 229 | 199 | 254 | 978 | 1,117 | |
| Operating Profit | -71 | -97 | -161 | -82 | 467 | 304 |
| OPM % | -334% | -73% | -415% | -48% | 32% | 21% |
| 1 | 4 | -526 | -143 | -94 | 5 | |
| Interest | 16 | 68 | 48 | 89 | 166 | 122 |
| Depreciation | 34 | 70 | 66 | 76 | 274 | 279 |
| Profit before tax | -121 | -231 | -800 | -391 | -68 | -92 |
| Tax % | 0% | -0% | 0% | 0% | -73% | -20% |
| -121 | -231 | -800 | -391 | -18 | -74 | |
| EPS in Rs | -1.57 | -6.44 | ||||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 131% |
| 3 Years: | 232% |
| TTM: | -2% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 8% |
| 3 Years: | 24% |
| TTM: | -161% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -18% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -10% |
| 3 Years: | -2% |
| Last Year: | -1% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 2 | 3 | 4 | 4 | 11 | 11 |
| Reserves | 774 | 1,009 | 781 | 392 | 5,869 | 5,820 |
| 386 | 1,154 | 864 | 562 | 772 | 1,504 | |
| 96 | 276 | 365 | 468 | 1,005 | 875 | |
| Total Liabilities | 1,258 | 2,442 | 2,015 | 1,426 | 7,657 | 8,210 |
| 633 | 1,231 | 1,361 | 863 | 6,118 | 6,233 | |
| CWIP | 431 | 490 | 334 | 188 | 218 | 314 |
| Investments | 0 | 0 | 4 | 20 | 16 | 16 |
| 195 | 722 | 314 | 356 | 1,305 | 1,648 | |
| Total Assets | 1,258 | 2,442 | 2,015 | 1,426 | 7,657 | 8,210 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| -118 | -416 | -163 | -107 | -68 | 9 | |
| -207 | -692 | -68 | 511 | -201 | -495 | |
| 381 | 1,162 | 118 | -391 | 412 | 359 | |
| Net Cash Flow | 56 | 54 | -112 | 13 | 143 | -127 |
| Free Cash Flow | -325 | -1,071 | -207 | -171 | -196 | -561 |
| CFO/OP | 164% | 430% | 108% | 130% | -13% | 6% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 38 | 65 | 36 | 117 | 105 | 177 |
| Inventory Days | 87 | 1,805 | 615 | 258 | 222 | 360 |
| Days Payable | 762 | 410 | 420 | 163 | 147 | 307 |
| Cash Conversion Cycle | -637 | 1,461 | 232 | 212 | 180 | 230 |
| Working Capital Days | -2,392 | -1,291 | -6,745 | -877 | -58 | -29 |
| ROCE % | -10% | -12% | -12% | 6% | 1% |
Insights
In beta| Dec 2023 | Mar 2025 | Mar 2026 | Mar 2027 (P) | Mar 2028 (P) | |
|---|---|---|---|---|---|
| Cartridge Installed Capacity (DDC) Million units per year |
|
||||
| Successful Regulatory and Customer Audits (Annual) Count |
|||||
| DDC Projects (Cumulative) Count |
|||||
| Device Platforms (DDC) Count |
|||||
| New MSAs / Licensing Agreements Signed (Annual) Count |
|||||
| Soft Gelatin Capsule Installed Capacity Billion units per year |
|||||
| Total Customers (Global) Count |
|||||
| Workforce Count |
|||||
Extracted by Screener AI
Documents
Announcements
-
Onesource Specialty Pharma And Formycon AG Announce
Strategic Manufacturing Partnership For Biosimilars
14 Jul - OneSource and Formycon AG announced a biosimilar manufacturing partnership in Bangalore on 14 July 2026.
-
Intimation Under Regulation 30 Of SEBI (LODR) Regulation, 2015
9 Jul - DRL semaglutide supply delay has no material impact; new capacities to start this quarter and later in 2026.
-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
8 Jul - Allotment of 24,190 equity shares of Re. 1/- under ONESOURCE ESOP 2021 on July 08, 2026.
-
Completion Of US-FDA Inspection At Sterile Product Division (SPD) Facility At Bengaluru
2 Jul - USFDA completed cGMP inspection at Bengaluru SPD facility, June 22-30, 2026, with one observation.
- Closure of Trading Window 24 Jun
Annual reports
Concalls
-
May 2026Transcript PPT REC
-
Jan 2026Transcript PPT REC
-
Nov 2025Transcript PPT REC
-
Sep 2025TranscriptAI SummaryPPT
-
Aug 2025Transcript PPT REC
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT
Business Overview:[1]
OSSPL is a subsidiary of Strides Pharma
Ltd. The company is a Contract Development
and Manufacturing Organisation that caters
to several biopharma and biotech companies.
It covers the entire CDMO value chain, from clinical development to technology transfer
to commercial manufacture and regulatory assistance.